US4401671A - Treatment of giardiasis and trichomoniasis - Google Patents
Treatment of giardiasis and trichomoniasis Download PDFInfo
- Publication number
- US4401671A US4401671A US06/347,655 US34765582A US4401671A US 4401671 A US4401671 A US 4401671A US 34765582 A US34765582 A US 34765582A US 4401671 A US4401671 A US 4401671A
- Authority
- US
- United States
- Prior art keywords
- giardiasis
- trichomoniasis
- treatment
- fluorouracil
- emimycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Giardia lamblia a parasite that until recently was widely believed to be relatively harmless, now heads the list of the most common intestinal parasitic infections in the United States and some other countries.
- the parasite causes a diarrheal disease call giardiasis.
- This infection causes a variety of intestinal symptoms, such as prolonged diarrhea, abdominal cramps, stomach pain, severe weight loss, fatigue, nausea and flatulence.
- Giardiasis can also cause malabsorption of nutrients and even retarded growth. Furthermore, giardiasis can mimic the symptoms of other conditions such as ulcers and gall bladder attacks. If misdiagnosed, a patient may have a series of costly, needless tests, and even surgery.
- the infection can be successfully treated with one of three drugs: Atabrine, Flagyl or furazolidione.
- Atabrine Atabrine
- Flagyl Atabrine
- furazolidione Atabrine
- each of these drugs is known to cause adverse side effects.
- no prophylactic drug ash been found which can adequately protect against giardiasis. (L. K. Altman, M.D., The New York Times, June 10, 1980).
- Trichomoniasis is an infection of the lower genito-urinary tract, which may be induced in men and women by the protozoan parasite Trichomonas vaginalis.
- the infection may produce a few symptoms of such extreme discomfort and morbidity that intervention from a gynecologist or a urologist is necessary.
- the disease is of cosmopolitan distribution and apparently 10-25% of sexually mature females and 25-80% of their consorts are involved (E. A. Steck, The Chemotherapy of Protozoan Diseases, Vol. II, Section 3, 17-1 (1971).
- Trichomoniasis is presently treated with Flagyl(metronidazole).
- the present invention relates to the use of 5-fluoro-2,4-(1H, 3H)pyrimidenedione (fluorouracil) or 2-hydroxypyrazine-4-oxide(emimycin) in the treatment of giardiasis and trichomoniasis in humans.
- the present invention is directed to the novel method for control and treatment of giardiasis, a parasitic infection in humans caused by protozoa of the genus Giardia.
- novel compositions used in the present method can also be used for the prevention, treatment and control of trichomoniasis in men and women.
- a nutrient medium for example, the modified Diamond's TPS medium at pH 7.05, together with about 10% by volume of heat-inactivated serum and about 1% by volume of antibiotic-antimycotic solution is placed in each well of a multiwell plate.
- a nutrient medium for example, the modified Diamond's TPS medium at pH 7.05
- an aliquot of a suspension of G. lamblia cells containing about 10 6 organisms is added.
- each well is inoculated with a known concentration of one of the active compounds.
- the multiwell plate containing the individual culture samples is incubated under anaerobic conditions at about 37° C. for about 16-24 hrs. The number of viable cells remaining in each well are then counted, such as with a hemacytometer.
- the percentage of survival is determined by comparison with controls inoculated with DMSO (dimethylsulfoxide) and the effective concentration (in parts per million) for 50% inhibition of growth (ED 50 ) is determined. It is established that the lower the number of the value of ED 50 , the higher the activity of the active compound.
- DMSO dimethylsulfoxide
- the novel method of this invention comprises the administration of fluorouracil or emimycin as an anti-giardiasis or anti-trichomoniasis agent to a human patient in amounts ranging from about 0.05 to about 50 mg. per kg. of body weight, preferably from about 0.25 to about 25 mg. per kg. of body weight in a single dose or in 2 to 4 divided doses.
- the oral phamaceutical compositions of this invention usually consist of an active compound and some appropriate excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like.
- the amount of an acitive compound in such a therapeutically useful composition or preparation usually ranges from about 2.5 mg. to about 2.5 g. preferably from about 5 mg. to about 500 mg. per unit dosage.
- the previously described tablets, troches, capsules, pills and the like usually contain one or more of the following inactive ingredients: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin and/or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- an excipient such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin and/or a flavor
- any material may be present as coatings or to otherwise modify the physical form of the dosage unit, for instance, tablets, pills, or capsules may be coated with shellac, sugar, or both.
- a syrup or elixir may contain the active compounds, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially nontoxic in the amounts employed.
- each well of a mutliwell plate is placed 1.4 ml of media mix containing Diamond's TPS medium (see Table 2) at pH 7.05, 10% by volume of heat-inactivated fetal bovine serum, and 1% by volume of an antibiotic-antimycotic solution (see Table 3).
- a suspension of Giardia lamblia is centrifuged at 2,500 ⁇ g. for 6 minutes. The cells are resuspended in a small volume of the Diamond's medium, counted, and each well inoculated with approximately 10 6 organisms.
- a stock solution of fluorouracil is made at a concentration of 150 ⁇ g/ml. The wells are then inoculated with various concentrations of the drug.
- the plates are incubated for 24 hours at 37° C. in an anaerobic Gas Pak jar. After 24 hours of incubation each well is mixed and counted for viable organisms using a hemacytometer. The percentage of survival is determined by comparing the treated wells to controls treated with dimethylsulfoxide.
- the in vitro anti-G. lamblia activity of fluorouracil is determined in terms of ED 50 (effect dosage for 50% inhibition of growth) and has a ED 50 value of 100 ppm.
- hydrochloride salts of the compounds are found to be equally active as the corresponding free base.
- emimycin and the pharmaceutically acceptable salts thereof are active anti-T. vaginalis agents as shown in Table 1.
- the active ingredient, starch and magnesium stearate are blended together.
- the mixture is used to fill hard shell gelatine capsules of a suitable size at a fill weight of 120 mg per capsule.
- the active ingredient, lactose and corn starch (for mix) are blended together.
- the corn starch (for paste) is suspended in water at a ratio of 10 grams of corn starch per 80 milliliters of water and heated with stirring to form a paste. This paste is then used to granulate the mixed powders.
- the wet granules are passed through a No. 8 screen and dried at 120° F.
- the dry granules are passed through a No. 16 screen.
- the mixture is lubricated with magnesium stearate and compressed into tablets in a suitable tableting machine. Each tablet contains 12 milligrams of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Fluorouracil and emimycin are useful in the treatment of giardiasis and trichomoniasis.
Description
Giardia lamblia, a parasite that until recently was widely believed to be relatively harmless, now heads the list of the most common intestinal parasitic infections in the United States and some other countries. The parasite causes a diarrheal disease call giardiasis.
This infection causes a variety of intestinal symptoms, such as prolonged diarrhea, abdominal cramps, stomach pain, severe weight loss, fatigue, nausea and flatulence.
Giardiasis can also cause malabsorption of nutrients and even retarded growth. Furthermore, giardiasis can mimic the symptoms of other conditions such as ulcers and gall bladder attacks. If misdiagnosed, a patient may have a series of costly, needless tests, and even surgery.
The infection can be successfully treated with one of three drugs: Atabrine, Flagyl or furazolidione. However, each of these drugs is known to cause adverse side effects. Until the present invention no prophylactic drug ash been found which can adequately protect against giardiasis. (L. K. Altman, M.D., The New York Times, June 10, 1980).
Trichomoniasis is an infection of the lower genito-urinary tract, which may be induced in men and women by the protozoan parasite Trichomonas vaginalis. The infection may produce a few symptoms of such extreme discomfort and morbidity that intervention from a gynecologist or a urologist is necessary. The disease is of cosmopolitan distribution and apparently 10-25% of sexually mature females and 25-80% of their consorts are involved (E. A. Steck, The Chemotherapy of Protozoan Diseases, Vol. II, Section 3, 17-1 (1971). Trichomoniasis is presently treated with Flagyl(metronidazole).
The present invention relates to the use of 5-fluoro-2,4-(1H, 3H)pyrimidenedione (fluorouracil) or 2-hydroxypyrazine-4-oxide(emimycin) in the treatment of giardiasis and trichomoniasis in humans.
The present invention is directed to the novel method for control and treatment of giardiasis, a parasitic infection in humans caused by protozoa of the genus Giardia.
The novel compositions used in the present method can also be used for the prevention, treatment and control of trichomoniasis in men and women.
Therefore, it is an object of the present invention to (1) provide novel pharmaceutical composition comprising fluorouracil or emimycin with anti-giardiasis and anti-trichomoniasis activities; (2) provide a novel method for the prevention, control and/or treatment of giardiasis and trichomoniasis in humans through the adminstration of the novel compositions.
The compounds useful in the novel methods of treatment of this invention have the following structural formulae: ##STR1##
The activity of these compounds against Giardia lamblia and Trichomonas foetus are shown by the following test:
About 1.0-2.0 ml of a nutrient medium, for example, the modified Diamond's TPS medium at pH 7.05, together with about 10% by volume of heat-inactivated serum and about 1% by volume of antibiotic-antimycotic solution is placed in each well of a multiwell plate. To this mixture, an aliquot of a suspension of G. lamblia cells containing about 106 organisms is added. Subsequently, each well is inoculated with a known concentration of one of the active compounds. The multiwell plate containing the individual culture samples is incubated under anaerobic conditions at about 37° C. for about 16-24 hrs. The number of viable cells remaining in each well are then counted, such as with a hemacytometer. The percentage of survival is determined by comparison with controls inoculated with DMSO (dimethylsulfoxide) and the effective concentration (in parts per million) for 50% inhibition of growth (ED50) is determined. It is established that the lower the number of the value of ED50, the higher the activity of the active compound. The ED50 values of the active compounds are summarized below in Table I.
TABLE 1
______________________________________
In vitro Anti-G. lamblia and Anti-T. foetus
activities of fluoruracil and emimycin
Anti-G. Anti-T.
lamblia foetus
Compound ED.sub.50 (ppm)
ED.sub.50 (ppm)
______________________________________
(1) fluorouracil
100 3
(2) emimycin 22.0 <1.0
______________________________________
The novel method of this invention comprises the administration of fluorouracil or emimycin as an anti-giardiasis or anti-trichomoniasis agent to a human patient in amounts ranging from about 0.05 to about 50 mg. per kg. of body weight, preferably from about 0.25 to about 25 mg. per kg. of body weight in a single dose or in 2 to 4 divided doses.
These compounds in the described dosages are usually administered orally. They may also be administered to individuals by injection. The oral phamaceutical compositions of this invention usually consist of an active compound and some appropriate excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. The amount of an acitive compound in such a therapeutically useful composition or preparation usually ranges from about 2.5 mg. to about 2.5 g. preferably from about 5 mg. to about 500 mg. per unit dosage.
The previously described tablets, troches, capsules, pills and the like usually contain one or more of the following inactive ingredients: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin and/or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain in addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit, for instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. A syrup or elixir may contain the active compounds, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially nontoxic in the amounts employed.
In each well of a mutliwell plate is placed 1.4 ml of media mix containing Diamond's TPS medium (see Table 2) at pH 7.05, 10% by volume of heat-inactivated fetal bovine serum, and 1% by volume of an antibiotic-antimycotic solution (see Table 3). A suspension of Giardia lamblia is centrifuged at 2,500×g. for 6 minutes. The cells are resuspended in a small volume of the Diamond's medium, counted, and each well inoculated with approximately 106 organisms. A stock solution of fluorouracil is made at a concentration of 150 μg/ml. The wells are then inoculated with various concentrations of the drug. The plates are incubated for 24 hours at 37° C. in an anaerobic Gas Pak jar. After 24 hours of incubation each well is mixed and counted for viable organisms using a hemacytometer. The percentage of survival is determined by comparing the treated wells to controls treated with dimethylsulfoxide. The in vitro anti-G. lamblia activity of fluorouracil is determined in terms of ED50 (effect dosage for 50% inhibition of growth) and has a ED50 value of 100 ppm.
TABLE 2
______________________________________
Composition of Diamond's TPS Medium
Ingredients Amounts
______________________________________
Trypticase (BBL) 1.00 g
Panmede, liver digest P & B
2.00 g
Glucose 0.50 g
L-cysteine monohydrochloride
0.10 g
Ascorbic acid 0.02 g
Sodium chloride 0.05 g
Potassium phosphate-monobasic
0.06 g
Potassium phosphate, dibasic
0.10 g
anhydrous
Water, glass distilled
87.50 ml
pH adjusted to 7.0 with
1 N NaOH
______________________________________
TABLE 3 ______________________________________ Composition of antibiotic-antimycotic solution (100X) ______________________________________ Penicillin, 10,000 units Streptomycin 10,000 mcg. Fungizone ® 25 mcg. Prepared in 1 ml. of normal saline. ______________________________________
Employing substantially the similar procedure as described in Example 1 but substituting for fluorouracil used therein the other active compound emimycin, there is obtained similar results indicating the anti-G. lamblia activities of the compounds included above in Table 1.
Similarly, following essentially the same procedure described above, the hydrochloride salts of the compounds are found to be equally active as the corresponding free base.
Employing essentially the same method of Example 1, centrifuged cells of T. foetus KV1 are inoculated with fluorouracil at 37° C. for 24 hours. The results indicate that this compound is also an effective anti-T. foetus agent with an ED50 value of 3 ppm.
Similarly, emimycin and the pharmaceutically acceptable salts thereof are active anti-T. vaginalis agents as shown in Table 1.
______________________________________
Preparation of Capsule Formulation
Milligrams per
Ingredient Capsule
______________________________________
Fluorouracil 10
Starch 100
Magnesium Stearate
10
______________________________________
The active ingredient, starch and magnesium stearate are blended together. The mixture is used to fill hard shell gelatine capsules of a suitable size at a fill weight of 120 mg per capsule.
______________________________________
Preparation of Tablet Formulation
Milligrams per
Ingredient Capsule
______________________________________
Emimycin 12
Lactose 200
Corn starch (for mix)
50
Magnesium stearate
6
______________________________________
The active ingredient, lactose and corn starch (for mix) are blended together. The corn starch (for paste) is suspended in water at a ratio of 10 grams of corn starch per 80 milliliters of water and heated with stirring to form a paste. This paste is then used to granulate the mixed powders. The wet granules are passed through a No. 8 screen and dried at 120° F. The dry granules are passed through a No. 16 screen. The mixture is lubricated with magnesium stearate and compressed into tablets in a suitable tableting machine. Each tablet contains 12 milligrams of the active ingredient.
Claims (1)
1. A method of treating giardiasis in humans which comprises the administration to a person in need of such treatment of an effective antigiardiasis amount of 5-fluoro-2,4-(1H, 3H) pyrimidinedione.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/347,655 US4401671A (en) | 1982-02-10 | 1982-02-10 | Treatment of giardiasis and trichomoniasis |
| US06/421,595 US4424220A (en) | 1982-02-10 | 1982-09-22 | Treatment of giardiasis and trichomoniasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/347,655 US4401671A (en) | 1982-02-10 | 1982-02-10 | Treatment of giardiasis and trichomoniasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/421,595 Division US4424220A (en) | 1982-02-10 | 1982-09-22 | Treatment of giardiasis and trichomoniasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4401671A true US4401671A (en) | 1983-08-30 |
Family
ID=23364655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/347,655 Expired - Fee Related US4401671A (en) | 1982-02-10 | 1982-02-10 | Treatment of giardiasis and trichomoniasis |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4401671A (en) |
-
1982
- 1982-02-10 US US06/347,655 patent/US4401671A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Brotherton, Arzneim-Forsch 28 (10) (1978) pp. 1665-1672. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU684793B2 (en) | Pharmaceutical composition | |
| US6124337A (en) | Methods and formulations for modulating the human sexual response | |
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| EP0226266A2 (en) | Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments | |
| RO115780B1 (en) | SINERGICA COMBINATION | |
| US5922749A (en) | Medicaments for treating nausea and vomiting | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| US4021555A (en) | Pharmaceutical preparation and method for treatment of parkinsonism | |
| CA1109797A (en) | Treatment of rheumatoid arthritis and related diseases | |
| CA2087147A1 (en) | Method for administration of azauridine for the treatment of rheumatoid arthritis | |
| US4053617A (en) | 2,1,3-benzothiadiazoles as myolonolytics | |
| US4424220A (en) | Treatment of giardiasis and trichomoniasis | |
| US4401671A (en) | Treatment of giardiasis and trichomoniasis | |
| US4310541A (en) | Method of treating giardiasis and trichomoniasis | |
| US5116600A (en) | Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds | |
| JPH06500537A (en) | Use of arylhydroxyurea compounds for the treatment of atherosclerosis | |
| US4321274A (en) | Substituted 1-(cinnamylideneamino)-3-benzyli-deneaminoguanidines active against Giardia lamblia and Trichomonas vaginalis | |
| US4439450A (en) | Treatment of the blood-brain barrier with ibuprofen | |
| US5102883A (en) | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents | |
| Evans et al. | Nitrimidazine compared with metronidazole in the treatment of vaginal trichomoniasis | |
| US4954505A (en) | Use of oxoquinazoline derivatives in the treatment of hyperuricaemia | |
| US4946859A (en) | 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide | |
| US4321267A (en) | 1-Substituted-4 (1H)-pyridinone hydrazones active against Giardia lamblia and Trichomonas vaginalis | |
| US5686494A (en) | Pharmaceutical preparations for ameliorating epigastric functional disorders | |
| JP2002527472A (en) | Indigestion treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MERCK & CO., INC., LINCOLN AVE., CITY OF RAHWAY, N Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:WANG, CHING C.;REEL/FRAME:004130/0276 Effective date: 19820202 Owner name: MERCK & CO., INC., LINCOLN AVE., CITY OF RAHWAY, N Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WANG, CHING C.;REEL/FRAME:004130/0276 Effective date: 19820202 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19870830 |